Education
About Us
Working with TipRanks
Follow Us
Biontech Se Sponsored Adr (BNTX)
:BNTX
Top Page
BioNTech SE
(NASDAQ:BNTX)
Rating:61Neutral
Price Target:
$119.00
▲(9.20%Upside)
Positive Factors
Financial Agreements
BioNTech will receive a $1.5B upfront payment and is eligible for up to $7.6B in milestone payments from Bristol Myers, enhancing financial stability.
Market Potential
The collaboration could lead to more combinatory options, expanding BNT327's market potential by addressing more indications.
Strategic Partnerships
The strategic partnership with Bristol Myers for BNT327 is reminiscent of those with Pfizer for COMIRNATY, potentially providing competitive advantages.
Negative Factors
Competitive Position
BioNTech is considered to be solidly in second position in the race, behind ivonescimab.
Risks and Challenges
Risks include negative data for various BioNTech products, including BNT327.
BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.70B
Dividend YieldN/A
Average Volume (3M)1.12M
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth0.58%
EPS Growth-764.64%
CountryUS
Employees6,772
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.98
Shares Outstanding240,392,620
10 Day Avg. Volume1,602,746
30 Day Avg. Volume1,123,306
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio4.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$139.91Price Target Upside28.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
BioNTech SE Business Overview & Revenue Model
Company DescriptionBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
How the Company Makes MoneyBioNTech SE generates revenue through the development and commercialization of its mRNA-based therapies and vaccines. A significant portion of its income is derived from its collaboration with Pfizer, particularly from the sales of the COVID-19 vaccine, which has been distributed globally. The company also engages in strategic partnerships and licensing agreements with other pharmaceutical firms to enhance its development pipeline and expand its market reach. Additionally, BioNTech earns revenue through research grants and milestone payments associated with the progress of its clinical trials and product developments.
BioNTech SE Earnings Call Summary
Earnings Call Date:May 05, 2025
(Q1-2025)
| % Change Since: 3.84%|
Next Earnings Date:Aug 04, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a company that is making significant progress in its oncology programs and maintaining a strong financial position, despite experiencing decreased revenue and a higher net loss. The strategic investments in developing new therapies and preparing for future product launches are promising, but the financial losses and settlement expenses are notable challenges.Q1-2025 Updates
Positive Updates
Advancements in Oncology Programs
BioNTech presented new clinical data for their bispecific immunomodulator BNT327 and mRNA cancer immunotherapies, showing potential to establish new standards of care in oncology. They are advancing towards commercialization with the first BLA submission for BNT323 planned by the end of 2025.
COVID-19 Vaccine Developments
BioNTech is preparing for a variant-adapted COVID-19 vaccine rollout and maintains a strong financial position to support these developments.
Strong Financial Position
Despite a net loss, BioNTech ended the quarter with €15.9 billion in total cash plus security investments, indicating robust financial health.
Negative Updates
Decreased Revenue and Increased Net Loss
BioNTech reported total revenues of approximately €183 million for Q1 2025, a slight decrease from €188 million in Q1 2024. The net loss for the first quarter of 2025 was €416 million, compared to a net loss of €315 million in the prior-year period.
High R&D and Settlement Costs
R&D expenses increased to €526 million, driven by late-stage clinical studies. Additionally, BioNTech faced significant settlement costs with NIH and the University of Pennsylvania, totaling approximately US$1.2 billion.
Company Guidance
In BioNTech's first quarter 2025 earnings call, the company provided guidance on several key metrics. They reported total revenues of approximately €183 million for the quarter, primarily from COVID-19 vaccine sales, compared to €188 million in the first quarter of 2024, reflecting expected seasonality. BioNTech's research and development expenses reached €526 million, up from €508 million in the prior-year period, driven by the advancement of late-stage clinical studies, including those for BNT327. Selling, general, and administrative expenses were €121 million, down from €133 million due to reduced external services. The company recorded a net loss of €416 million, compared to a €315 million loss in the same period last year, with a basic and diluted loss per share of €1.73 versus €1.31 previously. BioNTech ended the quarter with a strong cash position of €15.9 billion, despite significant outflows related to acquisitions and settlements. For the full year, BioNTech reaffirmed its 2025 financial guidance, projecting revenues between €1.7 billion and €2.2 billion, R&D expenses from €2.6 billion to €2.8 billion, SG&A expenses between €650 million and €750 million, and capital expenditures ranging from €250 million to €350 million.BioNTech SE Financial Statement Overview
Summary
BioNTech showcases a robust balance sheet with a strong equity base and low debt, yet faces challenges with profitability and cash flow volatility. Addressing these operational issues is crucial for long-term growth.Income Statement
BioNTech's income statement reflects significant challenges in profitability. Recent TTM figures show negative net and EBIT margins, indicating operational inefficiencies. Although the company had strong revenue in previous years, recent declines highlight potential revenue instability.55
Neutral
Balance Sheet
BioNTech's balance sheet is robust, with a strong equity base and low levels of debt, resulting in a favorable debt-to-equity ratio. The equity ratio remains solid, underscoring financial stability. However, recent trends in reduced stockholders' equity warrant caution.70
Positive
Cash Flow
The cash flow analysis reveals a volatile free cash flow trend, with recent TTM figures showing a significant decline. While operating cash flow remains positive, the substantial drop in free cash flow raises concerns about cash management efficiency.60
Neutral
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 2.75B | 2.75B | 3.82B | 17.31B | 18.98B | 482.30M | Gross Profit |
| 2.17B | 2.21B | 3.22B | 14.32B | 16.07B | 423.00M | EBIT |
| -1.34B | -1.31B | 690.40M | 12.64B | 15.28B | -82.40M | EBITDA |
| -445.59M | -367.10M | 1.38B | 12.86B | 15.00B | -105.10M | Net Income Common Stockholders |
| -768.64M | -665.30M | 930.30M | 9.43B | 10.29B | 15.20M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 520.83M | 16.78B | 16.55B | 14.06B | 2.07B | 1.35B | Total Assets |
| 797.65M | 22.53B | 23.01B | 23.28B | 15.83B | 2.32B | Total Debt |
| 68.90M | 254.20M | 219.10M | 212.20M | 301.50M | 240.19M | Net Debt |
| -450.25M | -9.51B | -11.44B | -13.66B | -1.39B | -970.02M | Total Liabilities |
| 304.15M | 3.12B | 2.76B | 3.22B | 3.94B | 946.77M | Stockholders Equity |
| 493.49M | 19.41B | 20.25B | 20.06B | 11.89B | 1.37B |
| Cash Flow | Free Cash Flow | ||||
| -1.17B | -244.60M | 4.67B | 13.21B | 735.70M | -98.90M | Operating Cash Flow |
| -234.59M | 207.70M | 5.37B | 13.58B | 889.70M | -13.50M | Investing Cash Flow |
| 1.47B | -2.08B | -6.95B | -35.30M | -566.10M | -144.80M | Financing Cash Flow |
| -51.90M | -45.90M | -778.60M | -1.42B | 94.20M | 894.70M |
BioNTech SE Technical Analysis
Positive
108.97
Price Trends
99.64
Positive
105.45
Positive
108.51
Negative
Market Momentum
2.87
Negative
54.80
Neutral
49.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Positive. The current price of 108.97 is above the 20-day moving average (MA) of 101.73, above the 50-day MA of 99.64, and above the 200-day MA of 108.51, indicating a neutral trend. The MACD of 2.87 indicates Negative momentum. The RSI at 54.80 is Neutral, neither overbought nor oversold. The STOCH value of 49.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTX.
BioNTech SE Risk Analysis
BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNTech SE Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $14.06B | 12.82 | 22.69% | ― | 25.11% | 46.46% | |
70 Outperform | $35.93B | 42.02 | 17.33% | ― | 78.01% | ― | |
64 Neutral | $39.22B | ― | -414.62% | ― | 17.21% | 21.16% | |
61 Neutral | $25.70B | ― | -3.87% | ― | 0.58% | -764.64% | |
54 Neutral | $3.52B | ― | -51.57% | ― | 730.42% | 31.63% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
48 Neutral | $10.62B | ― | -29.34% | ― | -38.25% | 44.29% |
* Healthcare Sector Average
Performance Comparison
BNTX
BioNTech SE
106.89
8.09
8.19%
ALNY
Alnylam Pharma
302.46
146.03
93.35%
ARGX
Argenx Se
575.46
198.67
52.73%
GMAB
Genmab
22.84
-4.48
-16.40%
MRNA
Moderna
27.68
-120.71
-81.35%
SWTX
Springworks Therapeutics
46.74
7.82
20.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.